Regulatory News:
As of December 31, 2014, shares and voting rights outstanding of Essilor (Paris:EI), the world leader in ophthalmic optics, broke down as follows:
| December 31, 2014 | |||
| Shares outstanding | 215,892,528 | ||
| Exercisable voting rights | 228,568,667 | ||
|
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 232,528,588 |
(*) Shares held by the Company.
About Essilor
The world’s leading ophthalmic
optics company, Essilor designs, manufactures and markets a wide range
of lenses to correct and protect eyesight. Its corporate mission is to
improve vision to improve life. To support this mission, the Company
allocates more than €150 million to research and innovation every year,
in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux®,
Crizal®, Transitions®,
Definity®, Xperio®,
Optifog™, Foster Grant®, Bolon®
and Costa®. It also develops and markets
equipment, instruments and services for eyecare professionals.
Essilor
reported consolidated revenue of over €5 billion in 2013 and employs
more than 55,000 people. It distributes its products in some 100
countries with 28 plants, more than 450 prescription laboratories and
edging facilities, as well as several research and development centers
around the world.
For more information, please visit www.essilor.com.
The
Essilor share trades on the Euronext Paris market and is included in the
Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN:
FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
